NIFTY PHARMA Valuation Multiples
Benchmark index representing pharmaceutical formulations, active pharmaceutical ingredients (APIs), generic manufacturing, and global healthcare suppliers.
Consolidated TTM earnings multiple of constituent equities.
Price to book value of net assets across sector holdings.
Cash dividend yield distributed by constituent companies.
Relative to consolidated NIFTY 50 PE multiple (19.85).
NIFTY PHARMA Historical Valuation
PEOfficial historical valuation series. Benchmark 10Y median: 32.80
Historical PE data not available for this stock.
Official NSE Bhavcopy publishes equity P/E multiples for dividend/profit-earning companies. For companies with zero or negative earnings, PE is legitimately unquoted.
Compare the movement of the NIFTY 50 index value with its valuation multiple over the same period.
Historical trough and peak observations recorded since 2016.
Current PE of 41.00 trades at 25.0% above median.
Primary industry variable driving multiple expansion/contraction.
NIFTY PHARMA Constituent Equities (20 Stocks)
Official constituent basket with individual valuation and profile access.